Tvardi Therapeutics Inc (TVRD)
Tvardi Therapeutics Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ as common stock. The company is developing oral, small-molecule therapies aimed at inhibiting STAT3, a signaling pathway being studied for inflammatory and proliferative diseases with significant unmet need in the United States. Its lead candidate, TTI-101, is in Phase 1b/2 development for fibrosis-related conditions, including idiopathic pulmonary fibrosis, as well as hepatocellular carcinoma. Tvardi is also advancing TTI-109, an oral STAT3 inhibitor in Phase 1 testing. Founded in 2017, the company is based in Sugar Land, Texas.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TVRD
|
$1.92
|
22.4% Upside
|
Undervalued
|
$9.25
|
489.2% Upside
|
Bargain
|
Fair
|
0.0%
|
November 12, 2026
|
2.5x
|
20.942 M
|
5.322 M
|
0.7%
|
72.2%
|
-13.3
|
96.0%
|
